Third Wave Technologies' Invader,? MDS Pharma Services' Centralized ECG Service,? and Covance's StudyTracker?
Third Wave Technologies' (Madison, WI) Invader uses DNA and RNA analysis tools to search the double-helixed chains of the building blocks of life.
While the process was streamlined, the necessary liquid-handling stages were time-consuming.
That time can now be freed up, thanks to a supply agreement Third Wave made with 3M's (St. Paul, MN) Bioanalytical Technologies Project. 3M has developed microfluidic technology, which can reduce the amount of machinery needed by improved routing of interconnects. The end result will speed up the process without sacrificing the results.
The five Invader test fields will still be available: chromosomal analysis, infectious disease pharmacogenetics, hpv/women's health, and genetics. Leading tests include cystic fibrosis screens and diagnosis, risk factor for coagulation and cardiovascular disease, connexin 26, HPV genotyping, and drug response CYP450 2D6.
As with electronic data capture software products, there are quite a few genetic testing platforms available, without a dominant leader in either field. An alliance like this might be the needed advantage to win the crown.
Third Wave Technologies, (888) 898-2357, www.twt.com.
MDS Pharma Services (Montreal, QB) offered a strong suite of cardiovascular safety tests for six years, long before FDA guidelines indicated that it should be a standard part of drug development.
To make FDA's recent mandate more manageable, MDS created a centralized ECG service that offers a wealth of arrays, from one convenient source. The list includes specialized tests such as hERG K+ ion channel assays and Patch-Clamps to the more standard pharmacokinetic/pharmacodynamic tests. Most every test from preclinical to postmarketing is available (12-lead digital ECG recorder pictured above).
Testing is interpreted automatically and supervised by cardiologists. ECG interval measurements can be monitored. And the data generated from the tests is available from any Web site.
MDS Pharma Services also has over 900 beds devoted exclusively to Phase I trials, the most in the industry. It is a division of MDS, Inc. (Toronto, ON), a life sciences company which also focuses on drug discovery, development, and health care. The enormous (11,000+ employees) company began as a diagnostics lab. MDS has 30 years experience in the laboratory area.
MDS Pharma Services, (402) 476-2811, www.mdsps.com.
Covance's (Princeton, NJ) StudyTracker program was designed for people who don't work a nine-to-five but still want immediate service when they require data about their trial. StudyTracker recently passed the thousand-user mark, which makes it, technically speaking, a grand success.
To enter the StudyTracker Web site, users need to enter a constantly changing six-digit ID, matched up to a SecurID device, usually worn as a key ring or necklace. What's available for those who know the password is near-real-time data warehouse. Populating that warehouse is data and information for mammalian toxicology, bioanalytical, and metabolism data. Users can exchange files with Covance staff, review study schedules, create reports and then view them either on screen or as Comma Separated Values. StudyTracker launched in March 2001; Version 2 arrived in April 2003.
Covance says StudyTracker can save up to four hours a week since the information you need won't require playing a game of phone tag.
Covance, (609) 452-4440, www.covance.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.